Skip to main content
RARE logo

RARE · Ultragenyx Pharmaceutical Inc. · Executive Compensation

Track RARE — free
$17.38 -0.35 (-1.97%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.81B
Shares
101.92M
Volume · Nov 19 948.26K Avg daily vol (3M) 4.67M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Emil D. Kakkis $11,405,535
Erik Harris $4,045,072
Eric Crombez $4,002,173
Howard Horn $3,750,607
Karah Parschauer $3,509,313
Fiscal 2024
Executive Total
Emil D. Kakkis $13,717,687
Eric Crombez $4,298,223
Howard Horn $4,296,049
Erik Harris $4,295,813
John R. Pinion II $4,129,753
Fiscal 2023
Executive Total
Emil D. Kakkis $13,077,993
Howard Horn $5,941,040
Erik Harris $4,068,567
John R. Pinion II $4,049,853
Karah Parschauer $4,036,544
Fiscal 2022
Executive Total
Emil D. Kakkis $12,140,330
Mardi Dier $4,436,756
Camille Bedrosian $3,755,268
Erik Harris $3,748,555
John R. Pinion II $3,706,511
Fiscal 2021
Executive Total
Emil D. Kakkis $9,522,738
Camille Bedrosian $3,344,722
Mardi Dier $3,331,874
Erik Harris $3,317,210
John R. Pinion II $3,263,220
Fiscal 2020
Executive Total
Mardi Dier $6,120,642
Emil D. Kakkis $5,144,220
Erik Harris $2,224,299
Camille Bedrosian $2,214,680
John R. Pinion II $2,177,640
Shalini Sharp $793,249
Fiscal 2019
Executive Total
Emil D. Kakkis $6,553,142
John R. Pinion II $3,333,238
Shalini Sharp $2,572,184
Camille Bedrosian $2,485,654
Thomas Kassberg $2,456,501
Erik Harris $2,273,392
Fiscal 2018
Executive Total
Camille Bedrosian $4,836,128
Emil D. Kakkis $4,812,800
Shalini Sharp $2,027,960
Thomas Kassberg $1,692,660
John R. Pinion II $1,564,878
Erik Harris $641,070
Fiscal 2017
Executive Total
Emil D. Kakkis $6,684,899
Shalini Sharp $2,642,719
Thomas Kassberg $2,331,661
John R. Pinion II $1,919,329

Executive changes

Person Change Filed
Daniel G. Welch Appointed 2026-05-18
Shehnaaz Suliman, M.D. Already on the board
Since at least 2023: re-election or new board role
2026-05-18
Emil D. Kakkis, M.D., Ph.D. Already on the board
Since at least 2023: re-election or new board role
2026-05-18
Amrit Ray, M.D. Appointed 2025-05-19
Matthew K. Fust Appointed 2025-05-19
Corsee Sanders, Ph.D. Appointed 2024-06-21
Michael Narachi Appointed 2024-06-21
Deborah Dunsire, M.D. Appointed 2024-06-21
Howard Horn Appointed 2023-09-08
Howard Horn Appointed 2023-07-12
Daniel G. Welch Appointed 2023-06-13
Shehnaaz Suliman, M.D. Appointed 2023-06-13
Emil D. Kakkis, M.D., Ph.D. Appointed 2023-06-13
Lars Ekman, M.D., Ph.D.
“Dr. Ekman’s decision to retire from the Board is for personal reasons and is not related to any disagreement with the Company or its management on the Company’s operation, policies, or practices.”
Retired 2023-03-23
Eric Crombez, M.D. Appointed 2023-03-14
Mardi Dier Resigned 2022-11-10
Amrit Ray, M.D. Appointed 2022-04-22

Leadership

Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 293 filings 265 filers Visit website Investor relations